Midcap Stocks Research: Subscribe for 1 Year... Get Access for 3 Years
Here is the latest financial fact sheet of GLENMARK LIFE SCIENCES. For more details, see the GLENMARK LIFE SCIENCES quarterly results and GLENMARK LIFE SCIENCES share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | -0.9 |
No. of shares | m | 122.53 |
1 Week | % | -1.7 |
1 Month | % | 2.1 |
1 Year | % | 52.9 |
52 week H/L | Rs | 904.2/512.7 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
GLENMARK LIFE SCIENCES EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | NA | NA | NA | 800 | 534 | |
Low | Rs | NA | NA | NA | 376 | 369 | |
Sales per share (Unadj.) | Rs | 4,522.6 | 7,843.4 | 1,923.6 | 173.3 | 176.4 | |
Earnings per share (Unadj.) | Rs | 997.9 | 1,597.4 | 358.8 | 34.2 | 38.1 | |
Diluted earnings per share | Rs | 16.0 | 25.6 | 28.7 | 34.2 | 38.1 | |
Cash flow per share (Unadj.) | Rs | 1,096.2 | 1,747.3 | 392.8 | 37.3 | 41.5 | |
Dividends per share (Unadj.) | Rs | 0 | 0 | 0 | 21.00 | 21.00 | |
Adj. dividends per share | Rs | 0.00 | 0.00 | 0.00 | 21.00 | 21.00 | |
Avg Dividend yield | % | 0 | 0 | 0 | 3.6 | 4.7 | |
Book value per share (Unadj.) | Rs | 449.6 | 2,049.4 | 768.1 | 167.4 | 174.0 | |
Adj. book value per share | Rs | 7.2 | 32.8 | 61.4 | 167.4 | 174.0 | |
Shares outstanding (eoy) | m | 1.96 | 1.96 | 9.80 | 122.53 | 122.53 | |
Price / Sales ratio | x | 0 | 0 | 0 | 3.4 | 2.6 | |
Avg P/E ratio | x | 0 | 0 | 0 | 17.2 | 11.8 | |
P/CF ratio (eoy) | x | 0 | 0 | 0 | 15.8 | 10.9 | |
Price / Book Value ratio | x | 0 | 0 | 0 | 3.5 | 2.6 | |
Dividend payout | % | 0 | 0 | 0 | 61.5 | 55.1 | |
Avg Mkt Cap | Rs m | 0 | 0 | 0 | 72,043 | 55,321 | |
Total wages/salary | Rs m | 1,063 | 1,423 | 1,491 | 1,687 | 1,802 |
GLENMARK LIFE SCIENCES INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 8,864 | 15,373 | 18,852 | 21,232 | 21,612 | |
Other income | Rs m | 10 | 120 | 8 | 147 | 290 | |
Total revenues | Rs m | 8,874 | 15,493 | 18,860 | 21,379 | 21,902 | |
Gross profit | Rs m | 2,472 | 4,720 | 5,911 | 6,161 | 6,423 | |
Depreciation | Rs m | 193 | 294 | 334 | 379 | 421 | |
Interest | Rs m | 6 | 335 | 875 | 280 | 5 | |
Profit before tax | Rs m | 2,283 | 4,211 | 4,709 | 5,649 | 6,286 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 327 | 1,080 | 1,194 | 1,462 | 1,616 | |
Profit after tax | Rs m | 1,956 | 3,131 | 3,516 | 4,187 | 4,670 | |
Gross profit margin | % | 27.9 | 30.7 | 31.4 | 29.0 | 29.7 | |
Effective tax rate | % | 14.3 | 25.6 | 25.3 | 25.9 | 25.7 | |
Net profit margin | % | 22.1 | 20.4 | 18.6 | 19.7 | 21.6 |
GLENMARK LIFE SCIENCES BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 9,307 | 11,601 | 16,225 | 21,274 | 23,687 | |
Current liabilities | Rs m | 13,804 | 13,075 | 14,449 | 7,468 | 10,228 | |
Net working cap to sales | % | -50.7 | -9.6 | 9.4 | 65.0 | 62.3 | |
Current ratio | x | 0.7 | 0.9 | 1.1 | 2.8 | 2.3 | |
Inventory Days | Days | 3 | 2 | 2 | 3 | 2 | |
Debtors Days | Days | 185 | 152 | 120 | 116 | 136 | |
Net fixed assets | Rs m | 5,447 | 5,655 | 5,980 | 7,064 | 8,518 | |
Share capital | Rs m | 20 | 20 | 20 | 245 | 245 | |
"Free" reserves | Rs m | 862 | 3,997 | 7,508 | 20,263 | 21,070 | |
Net worth | Rs m | 881 | 4,017 | 7,527 | 20,508 | 21,315 | |
Long term debt | Rs m | 0 | 0 | 0 | 0 | 0 | |
Total assets | Rs m | 14,754 | 17,256 | 22,206 | 28,338 | 32,205 | |
Interest coverage | x | 378.4 | 13.6 | 6.4 | 21.2 | 1,150.2 | |
Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
Sales to assets ratio | x | 0.6 | 0.9 | 0.8 | 0.7 | 0.7 | |
Return on assets | % | 13.3 | 20.1 | 19.8 | 15.8 | 14.5 | |
Return on equity | % | 221.9 | 77.9 | 46.7 | 20.4 | 21.9 | |
Return on capital | % | 259.7 | 113.2 | 74.2 | 28.9 | 29.5 | |
Exports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Imports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Fx inflow | Rs m | 72 | 6,266 | 7,870 | 10,568 | 9,691 | |
Fx outflow | Rs m | 39 | 2,924 | 3,955 | 3,883 | 5,001 | |
Net fx | Rs m | 34 | 3,342 | 3,915 | 6,685 | 4,689 |
GLENMARK LIFE SCIENCES CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 104 | 1,950 | 3,881 | 5,976 | 3,134 | |
From Investments | Rs m | -89 | -505 | -687 | -1,222 | -1,541 | |
From Financial Activity | Rs m | 5 | -1,366 | -2,138 | -788 | -3,876 | |
Net Cashflow | Rs m | 21 | 79 | 1,056 | 3,966 | -2,283 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Glenn Saldanha | COMP SEC: Rudalf Corriea | YEAR OF INC: 2011 | BSE CODE: 543322 | FV (Rs): 2 | DIV YIELD (%): 2.5 |
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare GLENMARK LIFE SCIENCES With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
On Friday, Indian share markets traded on a positive note throughout the trading session and ended higher.